Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migrationassociated chemokine receptor expression

Rheumatology

Volumn 49, Issue 12, 2010, Pages 2264-2272

  Aerts, Nicolaas E ^a   De knop, Kathleen J ^a,b   Leysen, Julie ^a   Ebo, Didier G ^a,b   Bridts, Chris H ^a   Weyler, Joost J ^c   Stevens, Wim J ^a,b   De clerck, Luc S ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Adalimumab; Chemokine receptors; Interleukin 17; Rheumatoid arthritis; T lymphocytes; Tumour necrosis factor

Indexed keywords

ADALIMUMAB; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR6; GLUCOCORTICOID; INTERLEUKIN 17; INTERLEUKIN 4; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; HELPER CELL; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; RHEUMATOID ARTHRITIS; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT RESPONSE; UPREGULATION;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CHEMOKINES; FEMALE; HUMANS; INTERLEUKIN-17; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR NECROSIS FACTORS;

EID: 78549271154     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq224     Document Type: Article

References (51)

1. Sigidin YA, Loukina GV, Skurkovich B, Skurkovich S. Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. Scand J Rheumatol 2001;30:203-7.
2. Veys EM, Menkes CJ, Emery P. A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1997;40:62-8.
3. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003;278:1910-4.
4. Jovanovic DV, Di Battista JA, Martel-Pelletier J et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 1998;160: 3513-21.
5. Chu CQ, Swart D, Alcorn D, Tocker J, Elkon KB. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum 2007;56:1145-51.
6. Hofstetter HH, Ibrahim SM, Koczan D et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005;237: 123-30.
7. Lubberts E, Koenders MI, Oppers-Walgreen B et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004;50:650-9.
8. Chabaud M, Durand JM, Buchs N et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999;42:963-70.
9. Kotake S, Udagawa N, Takahashi N et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103: 1345-52.
10. Raza K, Falciani F, Curnow SJ et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005;7:R784-95.
11. Yamada H, Nakashima Y, Okazaki K et al. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:1299-304.
12. Eyerich K, Pennino D, Scarponi C et al. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J Allergy Clin Immunol 2009;123:59-66.
13. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 2008;128:2625-30.
14. Toda M, Leung DY, Molet S et al. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol 2003;111:875-81.
15. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 2008;181: 7420-7.
16. Nograles KE, Zaba LC, Shemer A et al. IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 2009;123:1244-52.
17. Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 2009; 60:1647-56.
18. Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204:1849-61.
19. Hirota K, Yoshitomi H, Hashimoto M et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 2007;204:2803-12.
20. Matsui T, Akahoshi T, Namai R et al. Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritis. Clin Exp Immunol 2001;125:155-61.
21. + mononuclear cells and enhances the production of IL-6. Cytokine 2009;47:112-8.
22. Ruth JH, Shahrara S, Park CC et al. Role of macrophage inflammatory protein-3alpha and its ligand CCR6 in rheumatoid arthritis. Lab Invest 2003;83: 579-88.
23. Homey B, Meller S, Savinko T, Alenius H, Lauerma A. Modulation of chemokines by staphylococcal superantigen in atopic dermatitis. Chem Immunol Allergy 2007;93:181-94.
24. Nakayama T, Fujisawa R, Yamada H et al. Inducible expression of a CC chemokine liver- and activation-regulated chemokine (LARC)/macrophage inflammatory protein (MIP)-3 alpha/CCL20 by epidermal keratinocytes and its role in atopic dermatitis. Int Immunol 2001;13:95-103.
25. Schmuth M, Neyer S, Rainer C et al. Expression of the C-C chemokine MIP-3 alpha/CCL20 in human epidermis with impaired permeability barrier function. Exp Dermatol 2002; 11:135-42.
26. Prevoo ML, van' t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
27. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23-31.
28. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39: 34-40.
29. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5: 549-53.
30. Melis L, Vandooren B, Kruithof E et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis 2010;69:618-23.
31. Shahrara S, Huang Q, Mandelin AM, Pope RM. TH-17 cells in rheumatoid arthritis. Arthritis Res Ther 2008;10: R93.
32. Kageyama Y, Ichikawa T, Nagafusa T, Torikai E, Shimazu M, Nagano A. Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis. Rheumatol Int 2007;28:137-43.
33. Kim KW, Cho ML, Park MK et al. Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor kappaB-dependent pathway in patients with rheumatoid arthritis. Arthritis Res Ther 2005;7: R139-48.
34. Kohno M, Tsutsumi A, Matsui H et al. Interleukin-17 gene expression in patients with rheumatoid arthritis. Mod Rheumatol 2008;18:15-22.
35. Yue C, You X, Zhao L et al. The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients. Rheumatol Int 2009; doi:10.1007/s00296-009-1179-x, 22 October 2009 [epub ahead of print].
36. Kattah MG, Wong MT, Yocum MD, Utz PJ. Cytokines secreted in response to Toll-like receptor ligand stimulation modulate differentiation of human Th17 cells. Arthritis Rheum 2008;58:1619-29.
37. Koenders MI, Lubberts E, van de Loo FA et al. Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J Immunol 2006;176:6262-9.
38. + regulatory T cells. Eur J Immunol 2008;38: 2512-27.
39. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-32.
40. Park H, Li Z, Yang XO et al. A distinct lineage of CD4T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-41.
41. Kelchtermans H, Schurgers E, Geboes L et al. Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma. Arthritis Res Ther 2009;11:R122.
42. + T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 1999; 42:2166-73.
43. Nissinen R, Leirisalo-Repo M, Peltomaa R, Palosuo T, Vaarala O. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann Rheum Dis 2004;63:681-7.
44. Schuerwegh AJ, Van Offel JF, Stevens WJ, Bridts CH, De Clerck LS. Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients. Rheumatology 2003;42: 541-8.
45. Popa C, Barrera P, Joosten LA et al. Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents. Eur Cytokine Netw 2009;20:88-93.
46. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 2008;205: 2491-7.
47. Zakharova M, Ziegler HK. Paradoxical anti-inflammatory actions of TNF-alpha: inhibition of IL-12 and IL-23 via TNF receptor 1 in macrophages and dendritic cells. J Immunol 2005;175:5024-33.
48. Tak PP, Taylor PC, Breedveld FC et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1077-81.
49. Aeberli D, Seitz M, Juni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology 2005;44:172-5.
50. Odai T, Matsunawa M, Takahashi R et al. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 2009;36:1158-65.
51. Kawashiri SY, Kawakami A, Iwamoto N et al. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs. J Rheumatol 2009;36:2397-402.